{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:27:15Z","timestamp":1793608035311,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001732","name":"Danish National Research Foundation","doi-asserted-by":"publisher","award":["DNRF164"],"award-info":[{"award-number":["DNRF164"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF22SA0081890"],"award-info":[{"award-number":["NNF22SA0081890"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129117","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:47:15Z","timestamp":1788569235000},"page":"129117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag\/catcher system enhances immunogenicity of a DNA vaccine in mice"],"prefix":"10.1016","volume":"92","author":[{"given":"Anna K.","family":"Okholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Fougeroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven H.","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren R.","family":"Paludan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A.","family":"de Jongh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam F.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2026.129117_bb0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0010","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.15190\/d.2021.1","article-title":"First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization","volume":"9","author":"Fortner","year":"2021","journal-title":"Discoveries"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129117_bb0015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2202669","article-title":"Delivering pandemic vaccines in 100 days \u2014 what will it take?","volume":"387","author":"Saville","year":"2022","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2026.129117_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2021.07.017","article-title":"Accelerated COVID-19 vaccine development: milestones, lessons, and prospects","author":"Bok","year":"2021","journal-title":"Immunity"},{"issue":"27","key":"10.1016\/j.vaccine.2026.129117_bb0025","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2026.129117_bb0030","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2026.129117_bb0035","series-title":"Moderna reports RSV vaccine 50% effective after 18 months","author":"Soucheray","year":"2024"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66734-2","article-title":"Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh","volume":"14","author":"Haq","year":"2024","journal-title":"Sci Rep"},{"issue":"6561","key":"10.1016\/j.vaccine.2026.129117_bb0045","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129117_bb0050","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00605-24","article-title":"Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and omicron BA.2 neutralization before and after first or second boosters","volume":"12","author":"Zhang","year":"2024","journal-title":"Microbiol Spectrum"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0055","article-title":"COVID-19 vaccines' protection over time and the need for booster doses; a systematic review","volume":"10","author":"Dadras","year":"2022","journal-title":"Arch Acad Emerg Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-39816-4","article-title":"Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2","volume":"14","author":"Hertz","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.129117_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9091033","article-title":"Challenges of storage and stability of mRNA-based COVID-19 vaccines","author":"Uddin","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129117_bb0070","article-title":"The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects","author":"Lu","year":"2024","journal-title":"Frontiers Media SA"},{"key":"10.1016\/j.vaccine.2026.129117_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178716","article-title":"DNA vaccines in the post-mRNA era: engineering, applications, and emerging innovations","author":"Neeli","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.129117_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA vaccines: history, molecular mechanisms and future perspectives","author":"Pagliari","year":"2023","journal-title":"J Mol Biol"},{"issue":"10332","key":"10.1016\/j.vaccine.2026.129117_bb0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129117_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019252","article-title":"In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers","volume":"6","author":"Vasan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.129117_bb0095","series-title":"The use of electroporation to deliver DNA-based vaccines","author":"Kisakov","year":"2024"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129117_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01123-25","article-title":"Lipid nanoparticle-encapsulated DNA vaccine induces balanced antibody and T-cell responses in pigs with maternally derived antibodies","volume":"99","author":"Lai","year":"2025","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101169","article-title":"Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters","volume":"32","author":"Liao","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.vaccine.2026.129117_bb0110","series-title":"Advances in biotechnology and the development of novel human vaccines","author":"Papadatou","year":"2025"},{"key":"10.1016\/j.vaccine.2026.129117_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2026.129117_bb0120","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","author":"Tariq","year":"2022","journal-title":"Front Media SA"},{"issue":"5138","key":"10.1016\/j.vaccine.2026.129117_bb0125","first-page":"1448","article-title":"The influence of antigen organization on B cell responsiveness","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science (1979)"},{"key":"10.1016\/j.vaccine.2026.129117_bb0130","doi-asserted-by":"crossref","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","author":"Bachmann","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20251-8","article-title":"Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity","volume":"12","author":"Fougeroux","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-016-0181-1","article-title":"Bacterial superglue enables easy development of efficient virus-like particle based vaccines","volume":"14","author":"Thrane","year":"2016","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129117_bb0145","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/S2666-5247(22)00337-8","article-title":"First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2","volume":"4","author":"Smit","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.129117_bb0150","unstructured":"NordicBavarian Bavarian nordic reports phase 3 Topline results for its COVID-19 booster vaccine candidate, 2023. Accessed: Jan 24, 2026. [Online]. Available: https:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=6807."},{"key":"10.1016\/j.vaccine.2026.129117_bb0155","unstructured":"Nordic Bavarian Bavarian Nordic provides update on COVID-19 booster vaccine program, 2023. Accessed: Jan 24, 2026. [Online] Available: https:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=6827."},{"issue":"6","key":"10.1016\/j.vaccine.2026.129117_bb0160","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41565-025-01889-1","article-title":"A modular mRNA vaccine platform encoding antigen-presenting capsid virus-like particles enhances the immunogenicity of the malaria antigen Pfs25","volume":"20","author":"Fougeroux","year":"2025","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129117_bb0165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/bit.21988","article-title":"Thermostability and molecular encapsulation within an engineered caged protein scaffold","volume":"101","author":"Dalmau","year":"2008","journal-title":"Biotechnol Bioeng"},{"issue":"24","key":"10.1016\/j.vaccine.2026.129117_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413534","article-title":"Signal peptides and their fragments in post-translation: novel insights of signal peptides","volume":"25","author":"Ono","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129117_bb0175","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1042\/BCJ20210015","article-title":"Evaluation of artificial signal peptides for secretion of two lysosomal enzymes in CHO cells","volume":"478","author":"Cheng","year":"2021","journal-title":"Biochem J"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129117_bb0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jmb.2013.10.021","article-title":"Structural analysis and optimization of the covalent association between SpyCatcher and a peptide tag","volume":"426","author":"Li","year":"2014","journal-title":"J Mol Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129117_bb0185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsinfecdis.2c00362","article-title":"Protein nanoparticle-mediated delivery of recombinant influenza hemagglutinin enhances immunogenicity and breadth of the antibody response","volume":"9","author":"Badten","year":"2023","journal-title":"ACS Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129117_bb0190","article-title":"Vaccine efficacy of self-assembled multimeric protein scaffold particles displaying the glycoprotein Gn head domain of rift valley fever virus","volume":"9","author":"Wichgers Schreur","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and outcomes of a plasmid DNA vaccine encoding the ERBB2 intracellular domain in patients with advanced-stage ERBB2-positive breast cancer: a phase 1 nonrandomized clinical trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129117_bb0200","first-page":"1","article-title":"Orientation of antigen display on self-assembling protein nanoparticles influences immunogenicity","volume":"9","author":"Schneider","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129117_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202729","article-title":"Nanovaccines displaying the influenza virus hemagglutinin in an inverted orientation elicit an enhanced stalk-directed antibody response","volume":"12","author":"Frey","year":"2023","journal-title":"Adv Healthc Mater"},{"issue":"42","key":"10.1016\/j.vaccine.2026.129117_bb0210","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1016\/j.vaccine.2008.07.074","article-title":"Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response","volume":"26","author":"Peacey","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129117_bb0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1128\/JVI.01811-07","article-title":"Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation","volume":"82","author":"Lacasse","year":"2008","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129117_bb0220","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1128\/JVI.79.2.717-724.2005","article-title":"Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies","volume":"79","author":"Ruedl","year":"2005","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129117_bb0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.virol.2009.09.012","article-title":"Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein","volume":"395","author":"Di Bonito","year":"2009","journal-title":"Virology"},{"issue":"MAR","key":"10.1016\/j.vaccine.2026.129117_bb0230","article-title":"Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines","volume":"8","author":"Gomes","year":"2017","journal-title":"Front Immunol"},{"issue":"7830","key":"10.1016\/j.vaccine.2026.129117_bb0235","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"7853","key":"10.1016\/j.vaccine.2026.129117_bb0240","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"issue":"30","key":"10.1016\/j.vaccine.2026.129117_bb0245","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1016\/j.vaccine.2021.05.098","article-title":"Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models","volume":"39","author":"Dey","year":"2021","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129117_bb0250","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00283-24","article-title":"Lipid nanoparticle-encapsulated DNA vaccine confers protection against swine and human-origin H1N1 influenza viruses","volume":"9","author":"Nguyen","year":"2024","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129117_bb0255","article-title":"Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity","volume":"6","author":"Tursi","year":"2025","journal-title":"Cell Rep Med"},{"issue":"42","key":"10.1016\/j.vaccine.2026.129117_bb0260","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2009.07.059","article-title":"DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies","volume":"27","author":"Bellier","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129117_bb0265","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","author":"Lu","year":"2020","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129117_bb0270","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/JLB.6A1021-535R","article-title":"Hemagglutinin-based DNA vaccines containing trimeric self-assembling nanoparticles confer protection against influenza","volume":"112","author":"Qiao","year":"2022","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.vaccine.2026.129117_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912898","article-title":"A mRNA vaccine encoding for a RBD 60-mer nanoparticle elicits neutralizing antibodies and protective immunity against the SARS-CoV-2 Delta variant in transgenic K18-hACE2 mice","volume":"13","author":"Brandys","year":"2022","journal-title":"Front Immunol"},{"issue":"33","key":"10.1016\/j.vaccine.2026.129117_bb0280","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2010.02.103","article-title":"Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies","volume":"28","author":"Jegerlehner","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:41:14Z","timestamp":1793605274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"alternative-id":["S0264410X26009266"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129117","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag\/catcher system enhances immunogenicity of a DNA vaccine in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129117"}}